Mutated ras peptides as vaccines in immunotherapy of cancer

Vox Sanguinis

Volumn 74, Issue SUPPL. 2, 1998, Pages 489-495

  Gjertsen, Marianne K ^a,b   Gaudernack, G ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; PROTEIN P21; RAS PROTEIN;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CODON; CONFERENCE PAPER; GENE MUTATION; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 0031818750     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1998.tb05462.x     Document Type: Conference Paper

References (49)

1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970. 13: 1.
2. Kawakami Y, Robbins PF, Genes coding for tumor antigens recognized by T lymphocytes. "Biologic therapy of cancer, Second ed. JB Lippincott Co. Philadelphia 1995: 53.
3. Rosenberg SA, Kawakami Y, Robbins PF, Wang R. Identification of the genes encoding cancer antigens: Implications for cancer immunotherapy. Adv Cancer Res. 1996. 70: 145.
4. obc, abl protein. Proc Natl Acad Sei USA. 1992.89: 1468.
5. Cheever MA. Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W. Immunity to oncogenic proteins. Immunol Rev. 1995. 145: 33.
6. Chen L, Thomas EK, Hu S-L, Hellstrøm I, Hellstrøm KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA. 1991. 88: 110.
7. Gedde-Dahl III T, Spurkland A, Eriksen JA., Thorsby E, Gaudernack G. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln→Leu61). Int. Immunol. 1992. 4: 1331.
8. Fossum B, Gedde-Dahl III T, Breivik J, Eriksen JA, Spurkland A, Thorsby E, Gaudernack G. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly→Asp). Int J Cancer. 1994, 56: 40.
9. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. 1988. Cell. 53: 549.
10. Capella G, Cronauer-Mitra S, Peinado MA, Perucho M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environmental Health Perspectives. 1991. 93: 125.
11. Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer. 1994. 69: 367.
12. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, Wynford-Thomas D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989. 4: 159.
13. Rodenhuis S, Slebos RJC. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. 1992. 52: 2665.
14. Ohashi K, Tsutsumi M, Nakajima Y, Nakano H, Konishi Y. Ki-ras point mutations and proliferation activity in biliary tract carcinomas. Br J Cancer. 1996. 74: 930.
15. Albino AP, Nanus DM, Mentle IR, CordonGardo C, McNutt NS, Bressler J, Andreeff M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 1989. 4: 1363.
16. Greenberg PD. Adoptive T cell therapy of tumors: Mechanisms operative in recognition and elimination of tumor cells. Adv Immunol. 1991, 49: 281.
17. Schwartz RH, A cell culture model for T lymphocyte clonal anergy. Science 1990, 248: 1349.
18. Allison JP. CD28-B7 interactions in T-cell activation. Curr Op Immunol. 1994, 6: 414.
19. Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J. Exp. Med. 1991, 73: 273.
20. Possum B, Gedde-Dahl III T, Hansen T, Eriksen JA, Thorsby E, Gaudemack G. Overlapping epitopes encompassing a point mutation (12Gly→Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. Eur J Immunol. 1993, 23: 2687.
21. Tsang KY, Nieroda CA, DeFilippi R, Chung YK, Yamaue H, Greiner JW, Schlom J. Induction of human cytotoxic T cell lines directed against point-mutated p21 ras-derived synthetic peptides. Vaccine Res. 1994, 3: 183.
22. Qin H, Chen W, Takahashi M, Disis ML, Byrd DR, Me Cahill L, Bertram KA, Fenton RG, Peace DJ, Cheever MA. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res. 1995. 55: 2984.
23. Van Elsas A, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJM, Schrier PI. Induction and characterization of cytotoxic T lymphocytes recognizing a mutated p21 ras peptide presented by HLA-A*0201. Int J Cancer. 1995, 61: 389.
24. Gedde-Dahl III T, Nilsen E, Thorsby E, Gaudernack G. Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras. Cancer Immunol Immunother. 1994b, 38: 127.
25. Possum B, Olsen AC, Thorsby E, Gaudernack, G. CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21 ras derived peptide (13Gly→Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol. Immunother. 1995, 40: 165.
26. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Sereide O, Thorsby E,Gaudemack G: Vaccination with mutant ras peptides and induction of T cell responsiveness in pancreatic-carcinoma patients after mutant ras peptide vaccination. Lancet 1995;346:1399-1400.
27. Gjertsen MK, Bakka A, Breivik J, Sasterdal I, Gedde-Dahl III T, Stokke KT, Solheim BG, Egge TS, Søreide O, Thorsby E, GaudernackG: Ex-vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase-I/II study. Int J Cancer 1996a;65:450-453.
28. Hsu FJ, Benike C, Fagnoni F, Lues TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. 1996. Nat Med. 2(1): 52.
29. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997;388(6644):782-787.
30. Steinmann RM. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol. 1991;9:271-296.
31. Gedde-Dahl III T, Spurkland A, Possum B, Wittinghofer A, Thorsby E, Gaudernack G. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA. Eur J Immunol. 1994a. 24: 410.
32. Johansen BH, Gedde-Dahl III T, Sollid LM, Vartdal F, Thorsby E, Gaudemack G. Binding of ras oncogene peptides to purified HLA-DQ (alpha 1*0102,beta 1*0602) molecules. Scand J Immunol. 1994. 39: 607.
33. Gjertsen MK, Sæterdal I, Thorsby E, Gaudernack G. Characterisation of immune responses in pancreatic carcinoma patients after mutant-p21-ras peptide vaccination. Brit J Cancer. 1996;74:1828-1833.
34. Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, Janeway Jr CA. Sequence analysis of peptides bound to MHC-class II molecules. Nature 1991;353:622-627.
35. d. Science 1992;256:1817.
36. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DAA, Strominger JL. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogenous in size. Nature 1992. 358: 764.
37. Gjertsen MK, Bjørheim J, Sæterdal I, Myklebust J, Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12-Val dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997;72:784-790.
38. Carreno BM, Turner RV, Biddison WE, Coligan JE. Overlapping epitopes that are recognized by CD8+ HLA class I-restricted and CD4+ class II-restricted cytotoxic T lymphocytes are contained within an influenza nucleoprotein peptide. J Immunol. 1992. 148: 894.
39. Perkins DL, Lai M-Z, Smith JA, Gefter ML. Identical peptides recognized by MHC class I-and class II-restricted T cells. J. Exp. Med. 1989. 170: 279.
40. Takahashi H, Germain RN, Moss B, et al. An immuno-dominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type I induces CD4 class II-restricted help for itself. J Exp Med. 1990. 171: 571.
41. Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells Dayt. 1994. 12 (2): 154.
42. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D. and Riddell, S. R. Reconstitution of cellular immunity against CMV in recipients of allogeneic bone marrow by adoptive transfer of T cell clones from the donor. N Engl J Med. 1995. 333: 1038.
43. Abrams SI, Dobrzanski MJ, Wells DT, Stanziale SF, Zaremba S, Masuelle L, Kantor JA, Schlom J. Petide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur J Immunol. 1995. 25: 2588.
44. Abrams SI, Stanziale SF, Lunin SD, Zaremba S, Schlom J. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. Eur J Immunol. 1996. 26: 435.
45. Jäger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M, Knuth A, Generation of cytotoxic T-cell responses with synthetic melanoma associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int J Cancer. 1966. 66: 162.
46. Jäger E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jäger D, Ilsemann C, Hagedorn M, Oesch F, Knuth A. Granulocyte-macrophage colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer. 1996c. 67: 54.
47. Disis ML, Bernhard H, Shiota FM et al. Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines. Blood 1996. 88: 202.
48. Jäger E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte-differentiation antigen expression in melanoma: Evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer. 1996. 66: 470.
49. Nomoto S, Nakao A, Kasai Y, Harada A, Nonami T, Takagi H. Detection of ras gene mutations in perioperative peripheral blood with pancreatic adenocarcinoma. Jpn J Cancer Res 1996;87:793-797.